Biodesix, Inc.

BDSX Healthcare Diagnostics & Research

Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.66 1.05 −4.25%
Market cap
$260.7M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
−7.46
Beneish M
−3.13
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 5 5
ROE
(302.55%) (383.09%) (316.53%) (540.01%)
ROA
(41.30%) (38.18%) (35.34%) (30.33%)
ROIC
(70.66%) (67.00%) (51.87%) (49.60%)
Return on Tangible Assets
(97.11%) (88.39%) (63.14%) (53.31%)
Average Days of Receivables
57.70 37.27 36.08 32.31
Free Cash Flow per Share
(3.91) (3.14) (2.61) (1.98)
Free Cash Flow
(29.33) (23.67) (25.25) (20.40)
Capital Expenditures
(1.18) (0.40) (0.41) (0.57)
Other line items
Cash ROIC
(47.30%) (37.01%) (31.10%) (23.73%)
Accounts Receivable Turnover
7.74 10.03 11.21 12.43
Accounts Payable Turnover
5.26 6.34 5.24 7.02
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
81.58 67.24 77.38 43.78
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
14.40% 13.56% 12.92% 11.93%
Selling, General and Administrative Expense of Revenue
105.76% 98.92% 95.07% 90.57%
Share Based Compensation of Revenue
5.40% 4.68% 4.46% 3.95%
Interest Coverage
(4.39) (3.61) (3.11) (2.55)
Operating CF/Net income
0.71 0.66 0.78 0.71
Depreciation/Fixed assets
0.28 0.28 0.29 0.29
Capex/Depreciation
(0.17) (0.06) (0.06) (0.08)
Revenue per Share
10.69 11.72 9.95 10.00
Operating CF per Share
(3.75) (3.08) (2.57) (1.93)
Capex per Share
(0.16) (0.05) (0.04) (0.06)
Capex to Sales
0.01 0.00 0.00 0.01

Fold the line items

Columns are period end dates